Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update

The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

(2017) Afsane Bahrami et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

p62 Promotes Amino Acid Sensitivity of mTOR Pathway and Hepatic Differentiation in Adult Liver Stem/Progenitor Cells

(2017) Masakazu Sugiyama et al.   JOURNAL OF CELLULAR PHYSIOLOGY

β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells

(2017) Nanbu Wang et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Mammalian target of rapamycin as a therapeutic target in osteoporosis

(2017) Gengyang Shen et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells

(2017) Qingyu Zeng et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Autophagy mediates cytotoxicity of human colorectal cancer cells treated with garcinielliptone FC

(2017) Shen-Jeu Won et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia

(2017) Cecilia Evangelisti et al.   JOURNAL OF CELLULAR PHYSIOLOGY

miR-199a-3p is involved in estrogen-mediated autophagy through the IGF-1/mTOR pathway in osteocyte-like MLO-Y4 cells

(2017) Jiayao Fu et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) José Baselga et al.   LANCET ONCOLOGY

Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis

(2017) J A Cutler et al.   LEUKEMIA

Therapeutic targeting of CK2 in acute and chronic leukemias

(2017) F Buontempo et al.   LEUKEMIA

Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics

(2017) S Reckel et al.   LEUKEMIA

mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph + and Ph-like B-ALL

(2017) Thanh-Trang T. Vo et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles

(2017) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness

(2017) Jordi Rodon et al.   Cancer Discovery

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells

(2017) Gabriele Stefanzl et al.   Oncotarget

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines

(2017) Simona Ultimo et al.   Oncotarget

The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation

(2017) Honyin Chiu et al.   Frontiers in Immunology

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

(2017) Jeffrey A Jones et al.   Lancet Haematology

Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism

(2017) Balaraman Kalyanaraman   Redox Biology

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL

(2017) Etai Adam et al.   Cancers

Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives

(2016) Michele Malagola et al.   ANNALS OF HEMATOLOGY

Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting

(2016) Francesca Chiarini et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia

(2016) Sarah K. Tasian et al.   BLOOD

4EBP1/c-MYC/PUMA and NF- B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

(2016) S. Yun et al.   BLOOD

Hypoxia promotes chemoresistance in acute lymphoblastic leukemia cell lines by modulating death signaling pathways

(2016) C. Petit et al.   BMC CANCER

Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience

(2016) L. Moscetti et al.   BREAST

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

(2016) Angel Guerrero-Zotano et al.   CANCER AND METASTASIS REVIEWS

The PI3K pathway in B cell metabolism

(2016) Julia Jellusova et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action

(2016) Davood Bashash et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer

(2016) Anya Alayev et al.   JOURNAL OF CELLULAR PHYSIOLOGY

LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors

(2016) Ying Cheng et al.   JOURNAL OF CLINICAL INVESTIGATION

Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia

(2016) Peter J. Siska et al.   JOURNAL OF IMMUNOLOGY

Class II Phosphoinositide 3-Kinases as Novel Drug Targets

(2016) Marco Falasca et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC and can be targeted by SYK inhibition

(2016) S Köhrer et al.   LEUKEMIA

The HK2 Dependent “Warburg Effect” and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate

(2016) Paweł Lis et al.   MOLECULES

Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes

(2016) YINGQIU XIE et al.   Oncology Letters

Glycogen Synthase Kinase-3β (GSK-3β) and Nuclear Factor Kappa-B (NFKB) in Childhood Acute Lymphoblastic Leukemia

(2016) Cristian Layton Tovar et al.   Advances in Clinical and Experimental Medicine

Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia

(2016) Ajoy Dias et al.   Current Hematologic Malignancy Reports

Ph-like acute lymphoblastic leukemia

(2016) T. H. Tran et al.   Hematology-American Society of Hematology Education Program

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors

(2016) Sherri Z. Millis et al.   JAMA Oncology

Hypoxia and Hypoxia-Inducible Factors in Leukemias

(2016) Margaux Deynoux et al.   Frontiers in Oncology

Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy

(2015) Xinlei Yu et al.   Autophagy

Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia

(2015) Huimin Geng et al.   CANCER CELL

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study

(2015) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363

(2015) James W. T. Yates et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting PI3K/AKT/mTOR network for treatment of leukemia

(2015) Jessika Bertacchini et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

(2015) N. Daver et al.   CLINICAL CANCER RESEARCH

Glucose addiction in cancer therapy: advances and drawbacks

(2015) Sara Granja et al.   CURRENT DRUG METABOLISM

The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia

(2015) J Eswaran et al.   LEUKEMIA

FOXO3a and Posttranslational Modifications Mediate Glucocorticoid Sensitivity in B-ALL

(2015) F. Consolaro et al.   MOLECULAR CANCER RESEARCH

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

(2015) S. M. Guichard et al.   MOLECULAR CANCER THERAPEUTICS

Kinase activity profiling reveals active signal transduction pathways in pediatric acute lymphoblastic leukemia: A new approach for target discovery

(2015) Naomi E. van der Sligte et al.   PROTEOMICS

Current treatment strategies for inhibiting mTOR in cancer

(2015) Francesca Chiarini et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex

(2015) P. Liu et al.   Cancer Discovery

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia

(2015) Stefano Iacovelli et al.   Oncotarget

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation

(2015) Carolina Simioni et al.   Oncotarget

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia

(2015) Jacky Wong et al.   Oncotarget

PI3K/AKT signaling pathway and cancer: an updated review

(2014) Miriam Martini et al.   ANNALS OF MEDICINE

Targeting miR-21 sensitizes Ph+ ALL Sup-b15 cells to imatinib-induced apoptosis through upregulation of PTEN

(2014) Wei-Zhang Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia

(2014) C. Shochat et al.   BLOOD

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

(2014) M. Y. Konopleva et al.   CLINICAL CANCER RESEARCH

Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels

(2014) A. M. Gomes et al.   HAEMATOLOGICA

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

(2014) Fabrice André et al.   LANCET ONCOLOGY

Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis

(2014) J Bertacchini et al.   LEUKEMIA

A revised definition for cure of childhood acute lymphoblastic leukemia

(2014) C H Pui et al.   LEUKEMIA

mTOR Inhibition by Everolimus in Childhood Acute Lymphoblastic Leukemia Induces Caspase-Independent Cell Death

(2014) Rana Baraz et al.   PLoS One

Differentiating mTOR inhibitors in renal cell carcinoma

(2013) Sumanta K. Pal et al.   CANCER TREATMENT REVIEWS

Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+acute lymphoblastic leukemia cells

(2013) Xi Yang et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

mTOR signaling for biological control and cancer

(2013) Anya Alayev et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region–Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib

(2013) Xiaomei Ren et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential

(2013) L M Neri et al.   LEUKEMIA

Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL)

(2013) Karolina Nemes et al.   PLoS One

Inhibition of PI3K/mTOR Overcomes Nilotinib Resistance in BCR-ABL1 Positive Leukemia Cells through Translational Down-Regulation of MDM2

(2013) Jie Ding et al.   PLoS One

Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia

(2013) Susanne Badura et al.   PLoS One

Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells

(2013) P. Casado et al.   Science Signaling

Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia

(2012) S. K. Tasian et al.   BLOOD

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

(2012) S. L. Maude et al.   BLOOD

Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment

(2012) Olga Frolova et al.   CANCER BIOLOGY & THERAPY

CALming Down T Cell Acute Leukemia

(2012) Emilio Hirsch et al.   CANCER CELL

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

(2012) M R Janes et al.   LEUKEMIA

The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line

(2012) Hongyun Xing et al.   LEUKEMIA RESEARCH

RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine

(2012) P O Saunders et al.   ONCOGENE

Antileukaemia effect of rapamycin alone or in combination with daunorubicin on ph+ acute lymphoblastic leukaemia cell line

(2011) Xi Yang et al.   HEMATOLOGICAL ONCOLOGY

Gain-of-function mutations ininterleukin-7 receptor-α(IL7R) in childhood acute lymphoblastic leukemias

(2011) Chen Shochat et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts

(2011) G Fuka et al.   LEUKEMIA

Targeting glycolysis in leukemia: A novel inhibitor 3-BrOP in combination with rapamycin

(2011) Lauren J. Akers et al.   LEUKEMIA RESEARCH

Autophagy as a target for anticancer therapy

(2011) Filip Janku et al.   Nature Reviews Clinical Oncology

Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia

(2011) Naoto Morishita et al.   PEDIATRIC BLOOD & CANCER

Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health

(2011) Kirsten K Ness et al.   Expert Review of Hematology

The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells

(2011) Y Kuwatsuka et al.   Blood Cancer Journal

Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells

(2010) Sven A. Lang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia

(2010) P. Saunders et al.   HAEMATOLOGICA

Control of Cell Survival and Proliferation by Mammalian Eukaryotic Initiation Factor 4B

(2010) D. Shahbazian et al.   MOLECULAR AND CELLULAR BIOLOGY

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia

(2009) Roman Crazzolara et al.   Autophagy

PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice

(2009) C. Peng et al.   BLOOD

Akt-dependent and -independent mechanisms of mTOR regulation in cancer

(2009) Regan M. Memmott et al.   CELLULAR SIGNALLING

Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms

(2009) E.A. Dunlop et al.   CELLULAR SIGNALLING

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The nuts and bolts of AGC protein kinases

(2009) Laura R. Pearce et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Charting the molecular network of the drug target Bcr-Abl

(2009) M. Brehme et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines

(2008) D. S. Levy et al.   BLOOD

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

(2008) N. Rhodes et al.   CANCER RESEARCH

Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1

(2008) M. Rosner et al.   HUMAN MOLECULAR GENETICS

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

(2008) Michael G. Kharas et al.   JOURNAL OF CLINICAL INVESTIGATION

Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor

(2008) Chikara Hirase et al.   LEUKEMIA RESEARCH

The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2

(2008) J. Huang et al.   MOLECULAR AND CELLULAR BIOLOGY

The CUL7 E3 Ubiquitin Ligase Targets Insulin Receptor Substrate 1 for Ubiquitin-Dependent Degradation

(2008) Xinsong Xu et al.   MOLECULAR CELL

PI3K/Akt: getting it right matters

(2008) T F Franke   ONCOGENE